MBX Biosciences, Inc. ((MBX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MBX Biosciences, Inc. is conducting an extension study titled An Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism Who Completed the 12-Week Treatment Period in the Phase 2 Study, MBX-2H1002 Study (Avail-Ext). The study aims to assess the long-term safety and tolerability of MBX 2109, a drug for treating hypoparathyroidism, a condition characterized by insufficient parathyroid hormone production.
The study tests MBX 2109, administered as a subcutaneous injection, in doses ranging from 200 µg to 1600 µg weekly. The drug is designed to manage hypoparathyroidism by supplementing the hormone deficiency.
This interventional study follows a non-randomized, crossover model without masking, focusing primarily on treatment. It seeks to provide insights into the drug’s long-term effects on patients who have completed a previous 12-week treatment period.
The study began on July 16, 2024, with its latest update submitted on November 11, 2024. The primary completion and estimated completion dates are yet to be disclosed, indicating the study is still in progress.
For investors, this study update could signal potential growth for MBX Biosciences if the results are positive, as it may lead to expanded treatment options for hypoparathyroidism. The ongoing recruitment and updates suggest active progress, which might influence investor sentiment favorably, especially in comparison to competitors lacking similar advancements.
The study is ongoing, with further details available on the ClinicalTrials portal.